Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2014

Open Access 01-12-2014 | Research

The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry

Authors: Laura Viviani, Anna Zolin, Anil Mehta, Hanne Vebert Olesen

Published in: Orphanet Journal of Rare Diseases | Issue 1/2014

Login to get access

Abstract

Background

Disease registries have the invaluable potential to provide an insight into the natural history of the disease under investigation, to provide useful information (e.g. through health indicators) for planning health care services and to identify suitable groups of patients for clinical trials enrolment. However, the establishment and maintenance of disease registries is a burdensome initiative from economical and organisational points of view and experience sharing on registries management is important to avoid waste of resources. The aim of this paper is to discuss the problems embedded in the institution and management of an international disease registry to warn against common mistakes that can derail the best of intentions: we share the experience of the European Cystic Fibrosis Society Patient Registry, which collects data on almost 30,000 patients from 23 countries.

Methods

We discuss the major problems that researchers often encounter in the creation and management of disease registries: definition of the aims the registry has to reach, definition of the criteria for patients referral to the registry, definition of the information to record, set up of a data quality process, handling of missing data, maintenance of data confidentiality, regulation of data use and dissemination of research results.

Results

We give examples on how many crucial aspects were solved by the European Cystic Fibrosis Society Patient Registry regarding objectives, inclusion criteria and variables definition, data management, data quality controls, missing data handling, confidentiality maintenance, data use and results dissemination.

Conclusions

We suggest an extensive literature research and discussions in working groups with different stake holders, including patient representatives, on the objectives, inclusion criteria and the information to record. We propose to pilot the recording of few variables and test the applicability of their definition first. The use of a shared electronic platform for data collection that automatically computes derived variables, and automatically performs basic data quality controls is a good data management practice, that also helps in reducing missing data. We found crucial for success the collaboration with existing national and international registries, cystic fibrosis organisations and patients’ associations.
Appendix
Available only for authorised users
Literature
1.
go back to reference Terracini B, Zanetti R: A short history of pathology registries, with emphasis on cancer registries. Soz Praventivmed. 2003, 48: 3-10. 10.1007/s000380300001.CrossRefPubMed Terracini B, Zanetti R: A short history of pathology registries, with emphasis on cancer registries. Soz Praventivmed. 2003, 48: 3-10. 10.1007/s000380300001.CrossRefPubMed
2.
go back to reference Porta M: A dictionary of Epidemiology.5th edition New York: Oxford University Press;2008. Porta M: A dictionary of Epidemiology.5th edition New York: Oxford University Press;2008.
6.
go back to reference Rabeneck L, Menke T, Simberkoff MS, Hartigan PM, Dickinson GM, Jensen PC, George WL, Goetz MB, Wray NP: Using the national registry of HIV-infected veterans in research: lessons for the development of disease registries. J Clin Epidemiol. 2001, 54: 1195-1203. 10.1016/S0895-4356(01)00397-3.CrossRefPubMed Rabeneck L, Menke T, Simberkoff MS, Hartigan PM, Dickinson GM, Jensen PC, George WL, Goetz MB, Wray NP: Using the national registry of HIV-infected veterans in research: lessons for the development of disease registries. J Clin Epidemiol. 2001, 54: 1195-1203. 10.1016/S0895-4356(01)00397-3.CrossRefPubMed
7.
go back to reference Strobl J, Enzer I, Bagust A, Haycox A, Smyth R, Ashby D, Walley T: Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registry. Pharmacoepidem Dr S. 2003, 12: 467-473. 10.1002/pds.804.CrossRef Strobl J, Enzer I, Bagust A, Haycox A, Smyth R, Ashby D, Walley T: Using disease registries for pharmacoepidemiological research: a case study of data from a cystic fibrosis registry. Pharmacoepidem Dr S. 2003, 12: 467-473. 10.1002/pds.804.CrossRef
8.
go back to reference Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M, Mastella G, Navarro J, Strandvik B, McKenzie S: European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulm. 2001, 31: 1-12. 10.1002/1099-0496(200101)31:1<1::AID-PPUL1000>3.0.CO;2-T.CrossRef Koch C, Cuppens H, Rainisio M, Madessani U, Harms H, Hodson M, Mastella G, Navarro J, Strandvik B, McKenzie S: European Epidemiologic Registry of Cystic Fibrosis (ERCF): comparison of major disease manifestations between patients with different classes of mutations. Pediatr Pulm. 2001, 31: 1-12. 10.1002/1099-0496(200101)31:1<1::AID-PPUL1000>3.0.CO;2-T.CrossRef
9.
go back to reference McCormick J, Mehta G, Olesen HV, Viviani L, Macek M, Mehta A: Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet. 2010, 375: 1007-1013. 10.1016/S0140-6736(09)62161-9.CrossRefPubMed McCormick J, Mehta G, Olesen HV, Viviani L, Macek M, Mehta A: Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis. Lancet. 2010, 375: 1007-1013. 10.1016/S0140-6736(09)62161-9.CrossRefPubMed
14.
go back to reference Mehta A: The how (and why) of disease registers. Early Hum Dev. 2010, 86: 723-728. 10.1016/j.earlhumdev.2010.08.006.CrossRefPubMed Mehta A: The how (and why) of disease registers. Early Hum Dev. 2010, 86: 723-728. 10.1016/j.earlhumdev.2010.08.006.CrossRefPubMed
17.
go back to reference Gibson LE, Cooke RE: A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine iontophoresis. Pediatrics. 1989, 23: 545-549. Gibson LE, Cooke RE: A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine iontophoresis. Pediatrics. 1989, 23: 545-549.
18.
go back to reference Hammond KB, Turcios NL, Gibson LE: Clinical evaluation of the macroduct sweat collecting system and conductivity analyser in the diagnosis of cystic fibrosis. J Pediatr. 1994, 124: 255-260. 10.1016/S0022-3476(94)70314-0.CrossRefPubMed Hammond KB, Turcios NL, Gibson LE: Clinical evaluation of the macroduct sweat collecting system and conductivity analyser in the diagnosis of cystic fibrosis. J Pediatr. 1994, 124: 255-260. 10.1016/S0022-3476(94)70314-0.CrossRefPubMed
19.
go back to reference Thomas M, Castellani C, Cuppens H, Gulmans V, Lemonnier L, Norek A, Vermeulen F, De Boeck K: WS3.2 Who is reported in the Belgian, Dutch and French CF registries?. J Cyst Fibros. 2012, 11: S6.CrossRef Thomas M, Castellani C, Cuppens H, Gulmans V, Lemonnier L, Norek A, Vermeulen F, De Boeck K: WS3.2 Who is reported in the Belgian, Dutch and French CF registries?. J Cyst Fibros. 2012, 11: S6.CrossRef
20.
go back to reference Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM: Evaluation of a new definition for chronic Pseudomonas aeruginosa in cystic fibrosis patients. J Cyst Fibros. 2003, 2: 29-34. 10.1016/S1569-1993(02)00141-8.CrossRefPubMed Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM: Evaluation of a new definition for chronic Pseudomonas aeruginosa in cystic fibrosis patients. J Cyst Fibros. 2003, 2: 29-34. 10.1016/S1569-1993(02)00141-8.CrossRefPubMed
27.
go back to reference Kerem E, Viviani L, Zolin A, Macneill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, Olesen H, on behalf of the ECFS Patient Registry Steering Group: Factors associated with FEV1 decline in cystic fibrosis: analysis of the data of the ECFS Patient Registry. Eur Respir J. 2013, 43: 125-133.CrossRefPubMed Kerem E, Viviani L, Zolin A, Macneill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V, Krivec U, Olesen H, on behalf of the ECFS Patient Registry Steering Group: Factors associated with FEV1 decline in cystic fibrosis: analysis of the data of the ECFS Patient Registry. Eur Respir J. 2013, 43: 125-133.CrossRefPubMed
28.
go back to reference Boëlle PY, Viviani L, Busson PF, Olesen HV, Ravilly S, Stern M, Assael BM, Barreto C, Drevinek P, Thomas M, Krivec U, Mei-Zahav M, Vibert JF, Clement A, Mehta A, Corvol H, French CF, Modifier Gene Study Investigators; European CF Registry Working Group: Reference percentiles for FEV1 and BMI in European children and adults with cystic fibrosis. Orphanet J Rare Dis. 2012, 1: 64.CrossRef Boëlle PY, Viviani L, Busson PF, Olesen HV, Ravilly S, Stern M, Assael BM, Barreto C, Drevinek P, Thomas M, Krivec U, Mei-Zahav M, Vibert JF, Clement A, Mehta A, Corvol H, French CF, Modifier Gene Study Investigators; European CF Registry Working Group: Reference percentiles for FEV1 and BMI in European children and adults with cystic fibrosis. Orphanet J Rare Dis. 2012, 1: 64.CrossRef
29.
go back to reference De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L: The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros. in press. De Boeck K, Zolin A, Cuppens H, Olesen HV, Viviani L: The relative frequency of CFTR mutation classes in European patients with cystic fibrosis. J Cyst Fibros. in press.
Metadata
Title
The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry
Authors
Laura Viviani
Anna Zolin
Anil Mehta
Hanne Vebert Olesen
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2014
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-9-81

Other articles of this Issue 1/2014

Orphanet Journal of Rare Diseases 1/2014 Go to the issue